Redeye reviews its take on Senzime following its establishment of a direct sales force in Germany while also factoring in a continued effect on its sales prospects due to Corona. We make slight downward adjustments to our shorter-term sales estimates, but our confidence in Senzime's ability to reach its SEK 200m sales target in 2023 remains. We repeat our positive view on the share and see a significant upside of 60%, likely to be ignited in H2 on the back of impressive revenue growth.